Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Camurati-Engelmann Syndrome × LY3300054 × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 1 fludarabine 1 Radiotherapy, Intensity-Modulated 1 LY3300054 1 Gemcitabine 1 Cyclophosphamide 1 Cisplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02937272 2025-10-20

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡